Table 3. Treatment outcomes and follow-up.

	IBT (n=53)		TSRWH (n=19)		P-valuea
	n	%	n	%
Final VA (Snellen-20 feet)b
<20/200	33	68.8	7	46.7	0.121
≥20/200	15	31.2	8	53.3
Metastatic disease
No	39	73.6	16	84.2	0.531
Yes	14	26.4	3	15.8
Local recurrence
No	50	94.3	17	89.5	0.602
Yes	3	5.7	2	10.5
Enucleation
No	48	90.6	15	78.9	0.231
Yes	5	9.4	4	21.1
Enucleation cause
Local recurrence	3	5.7	2	10.5	0.602
NVG	2	3.8	0	0	≥0.999
Corneal oedema	0	0	2	10.5	0.067
Overall death
No	47	88.7	17	89.5	≥0.999
Yes	6	11.3	2	10.5
Specific death
No	48	90.6	17	89.5	≥0.999
Yes	5	9.4	2	10.5
Parameters with MCT	Mean or median	SD (range) or IQR (range)	Mean or median	SD (range) or IQR (range)	P-valuea
Final VA (Snellen chart)b	20/20 000	20/160 (20/200 000–20/25)	20/200	20/34 (20/20 000–20/20)	0.027
Final VA (LogMAR)b	3	2.15 (0.1–4.0)	1	1.78 (0–3.0)	0.029
Follow-up (months)c	55.9	28.6 (9.6–107.8)	50.9	25.6 (9.6–102.5)	0.506

Abbreviations: IBT, iodine-125 brachytherapy; IQR, interquartile range; MCT, measures of central tendency; NVG, neovascular glaucoma; TSRWH, transscleral resection performed without hypotensive anaesthesia; VA, visual acuity.

Median with IQR (range) were obtained for Snellen chart and LogMAR.

^aP-values were obtained by χ²-test (final VA<20/20 and ≥20/200) or Fisher's exact test (metastatic disease, local recurrence, enucleation, enucleation cause, overall death, and specific death) as needed for the qualitative variables, and by Mann–Whitney's U-test (final VA Snellen and LogMAR) or Student's t-test (follow-up) as needed for the quantitative variables.

^bEnucleated patients were excluded of BCVA analysis.

^cMean, SD, and range were obtained for the follow-up. The bold values indicate P<0.05.